ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Rhea-AI Summary

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, has announced its participation in the 37th Annual Roth Conference. Neil Warma, the company's CEO, will engage in a fireside chat on March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.

The company focuses on developing treatments targeting toxic misfolded proteins in three main areas:

• Alzheimer's disease (AD)
• Amyotrophic lateral sclerosis (ALS)
• Multiple system atrophy (MSA)

A live webcast of the presentation will be available on the Events page of ProMIS Neurosciences' website and will remain accessible for at least 30 days after the event.

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37^th Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to selectively bind oligomers. PMN 310 has successfully completed a Phase 1a clinical study and is dosing Alzheimer’s disease patients in a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.

For further information:

Visit us at www.promisneurosciences.com.

Please submit media inquiries to info@promisneurosciences.com.

For Investor Relations, please contact:

Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200

 

FAQ

When is ProMIS Neurosciences (PMN) presenting at the Roth Conference 2025?

ProMIS Neurosciences will present on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.

What therapeutic areas does ProMIS Neurosciences (PMN) focus on?

ProMIS focuses on antibody therapeutics targeting toxic misfolded proteins in Alzheimer's disease, ALS, and multiple system atrophy.

How can investors watch ProMIS Neurosciences' (PMN) Roth Conference presentation?

Investors can access the live webcast through the Events page on ProMIS Neurosciences' website (www.promisneurosciences.com).

How long will ProMIS Neurosciences' (PMN) Roth Conference webcast be available?

The webcast will be available for at least 30 days following the event on the company's website.